Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Oncology Center of Excellence

Oncology Center of Excellence

                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community Home
          About FDA
          FDA Organization
          Oncology Center of Excellence
          Project FrontRunnerOncology Center of Excellence Project FrontRunner
  
  					Advancing Development of New Oncology Therapies to the Early Clinical Setting
	
    Share
    Post
    Linkedin

    Email
    PrintImage
              Project FrontRunnerWhat is Project FrontRunner?

**Project FrontRunner** is an Oncology Center of Excellence (OCE) initiative to encourage drug sponsors to consider when it may be appropriate to first develop and seek approval of new cancer drugs for advanced or metastatic disease, in an earlier clinical setting rather than the usual approach to develop and seek approval of a new drug  for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options.

Designing trials that support initial approval in the earlier setting may provide  the following advantages:

Earlier access to new therapies: Initiating the clinical investigation of new therapies in an earlier treatment setting can provide more patients the opportunity to receive the investigational agent early enough in the disease course when disease-related factors do not preclude participation in the trial, and when the treatment has the potential to alter the course of the disease more effectively.
	Improved assessment of drug effects. There is greater opportunity to characterize the drug’s safety profile while avoiding the confounding effects of disease-related complications or sequelae of prior treatment.
	Elucidates drug effects  of new therapies compared to established standard of care. Randomized controlled trials which are the gold standard in characterizing new drug safety and effectiveness are less challenging to conduct early in the course of advanced/metastatic disease (e.g., first or second line setting) due to larger patient numbers and identifiable effective treatments to compare the new drug to, factors which may lacking in a more advanced treatment setting.
	Potential to improve treatments in the frontline setting. With the increase in the number of approved cancer treatments, there is a need to continually optimize treatment strategies for newly diagnosed patients with metastatic disease. While treatments in the frontline setting for many diseases may provide improvements in survival, better treatment options either as add-ons to or replacements of current non-curative and often very toxic treatments.What are Project FrontRunner Goals?

Develop a framework for identifying candidate drugs that are appropriate to  initially develop for the treatment of early metastatic disease (e.g., first or second line setting), taking into account clinical, scientific, regulatory, and operational considerations.
	Facilitate engagement with drug sponsors during drug development to develop and implement strategies to support approvals in early clinical setting.
	Engage and collaborate with internal and external stakeholders on related research, policy, and educational initiatives.What is the Scope of Project FrontRunner?

The initial focus for Project FrontRunner is for drugs being developed for treatment in the advanced/metastatic setting, typically where treatment is not expected to be curative. In this setting, advancing new effective therapies has the greatest potential to significantly improve quantity and quality of patients’ lives.

Will FDA incorporate external stakeholder perspectives in Project FrontRunner related activities?

FDA continues to identify mechanisms to engage with stakeholders to understand the opportunities and potential challenges related to this drug development paradigm, through symposia and listening sessions, and through collaborative projects.

Will FDA require that sponsors follow the Project FrontRunner paradigm?

As is always the case, FDA provides recommendations to sponsors on the best approach to developing new drugs for the treatment of cancer. In the right context, the Project FrontRunner paradigm may be appropriate for sponsors to consider.

Could Project FrontRunner discourage sponsors from developing drugs in the more refractory settings?

FDA recognizes the need to address the unmet need for treatments for patients who have received many prior treatments, and this will remain a priority for the OCE. Use of expedited programs that support drug development programs that address an unmet need continues to be strongly encouraged. Project FrontRunner aims to improve the evidence base for cancer therapies by promoting trial designs and clinical development and regulatory approaches (e.g., accelerated approval pathway) that help generate data from gold standard randomized controlled trials to support the safe and effective use of cancer therapies for all patients.



**Program Lead: Lola Fashoyin-Aje**, MD, MPH, Associate Director (acting), Oncology Center of Excellence

**Project Management: Caitlin Drew, RN**, MSN, Senior Regulatory Health Project Manager, Oncology Center of Excellence



Publications and Interviews

Cobb J. FDA’s Fashoyin-Aje: Draft guidance on accelerated approval urges reliance on randomized controlled trials. The Cancer Letter, 2023, March 31; Vol. 49 No. 13
	Fashoyin-Aje LA, Mehta GU, Beaver JA, Pazdur R. The On- and Off-Ramps of Oncology Accelerated Approval. N Engl J Med. 2022 Oct 20;387(16):1439-1442. doi: 10.1056/NEJMp2208954. Epub 2022 Sep 21. PMID: 36129992.
	Goldberg, P. FDA spells out new systematic approach to giving out–and taking away–accelerated approvals in oncology. The Cancer Letter, 2022 Sept. 23; Vol.48 No.34Additional Resources

Project Optimus
	Project Confirm

                                                                                  Content current as of:
      04/13/2023Oncology Center of Excellence

          
                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop